133 related articles for article (PubMed ID: 27908728)
21. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.
Zhang SJ; Ma LY; Huang QH; Li G; Gu BW; Gao XD; Shi JY; Wang YY; Gao L; Cai X; Ren RB; Zhu J; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2076-81. PubMed ID: 18250304
[TBL] [Abstract][Full Text] [Related]
22. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
Tanaka A
Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
[TBL] [Abstract][Full Text] [Related]
23. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
Ng HL; Robinson ME; May PC; Innes AJ; Hiemeyer C; Feldhahn N
Br J Haematol; 2024 Mar; 204(3):945-958. PubMed ID: 38296260
[TBL] [Abstract][Full Text] [Related]
24. Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia.
Wang L; Chen Y; Wang Q; Xiang M; Zeng Z; Zhang Z; Zhang F; Chen S; Xue M
Int J Lab Hematol; 2024 Jun; 46(3):571-574. PubMed ID: 38389449
[No Abstract] [Full Text] [Related]
25. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide.
Zhang Y; Sicot G; Cui X; Vogel M; Wuertzer CA; Lezon-Geyda K; Wheeler J; Harki DA; Muzikar KA; Stolper DA; Dervan PB; Perkins AS
Biochemistry; 2011 Dec; 50(48):10431-41. PubMed ID: 22039883
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.
Imeri J; Marcoux P; Huyghe M; Desterke C; Fantacini DMC; Griscelli F; Covas DT; de Souza LEB; Griscelli AB; Turhan AG
Front Immunol; 2023; 14():1309010. PubMed ID: 38259442
[TBL] [Abstract][Full Text] [Related]
27. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract][Full Text] [Related]
28.
Pellicano F; Park L; Hopcroft LEM; Shah MM; Jackson L; Scott MT; Clarke CJ; Sinclair A; Abraham SA; Hair A; Helgason GV; Aspinall-O'Dea M; Bhatia R; Leone G; Kranc KR; Whetton AD; Holyoake TL
Blood; 2018 Apr; 131(14):1532-1544. PubMed ID: 29437554
[TBL] [Abstract][Full Text] [Related]
29. Accelerated-phase CML: de novo and transformed.
Shanmuganathan N; Hughes TP
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):459-468. PubMed ID: 38066863
[TBL] [Abstract][Full Text] [Related]
30. CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.
Absar M; Alanazi N; Siyal A; Shammas M; Mahmood A; Basit S; AlMukhaylid S; Iqbal Z
J Popul Ther Clin Pharmacol; 2022 Jun; 29(2):311-320. PubMed ID: 38465242
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts.
Griffiths EA; Golding MC; Srivastava P; Povinelli BJ; James SR; Ford LA; Wetzler M; Wang ES; Nemeth MJ
Haematologica; 2015 Feb; 100(2):e49-52. PubMed ID: 25381132
[No Abstract] [Full Text] [Related]
32. Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia.
Vijaya Prakash A; Sivakolundu KP; Savage NM; Kota VK; Shoukier M
Cureus; 2021 Sep; 13(9):e18368. PubMed ID: 34729261
[TBL] [Abstract][Full Text] [Related]
33. Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia.
Spinler K; Hamilton M; Bajaj J; Shima Y; Diaz E; Kritzik M; Reya T
bioRxiv; 2023 Dec; ():. PubMed ID: 38234720
[TBL] [Abstract][Full Text] [Related]
34. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Scott MT; Liu W; Mitchell R; Clarke CJ; Kinstrie R; Warren F; Almasoudi H; Stevens T; Dunn K; Pritchard J; Drotar ME; Michie AM; Jørgensen HG; Higgins B; Copland M; Vetrie D
Nat Commun; 2024 Jan; 15(1):651. PubMed ID: 38246924
[TBL] [Abstract][Full Text] [Related]
35. Establishment of the Myeloid TBX-Code Reveals Aberrant Expression of T-Box Gene TBX1 in Chronic Myeloid Leukemia.
Nagel S; Haake J; Pommerenke C; Meyer C; MacLeod RAF
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203204
[TBL] [Abstract][Full Text] [Related]
36. RNA binding protein Lin28B promotes chronic myeloid leukemia blast crisis by transcriptionally upregulating miR-181d.
Zhou M; Yin X; Zhang L; Cui Z; Jiang X; Ji Q; Ma S; Chen C
Mol Cancer Res; 2024 Jun; ():. PubMed ID: 38847604
[TBL] [Abstract][Full Text] [Related]
37. Extramedullary T-lymphoblastic blast crisis in a young male with chronic myeloid leukemia: A rare presentation diagnosed on cytology and flow cytometric immunophenotyping.
Kaur G; Gupta P; Mallik N; Gupta N; Sachdeva MUS; Malhotra P
Diagn Cytopathol; 2024 Jun; ():. PubMed ID: 38887193
[TBL] [Abstract][Full Text] [Related]
38. Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
Menshawy NE; El-Ghonemy MS; Ebrahim MA; Fahmi MW; Saif M; Denewer M; El-Ashwah S
Ann Hematol; 2024 May; ():. PubMed ID: 38710877
[TBL] [Abstract][Full Text] [Related]
39. A Case of Leukemic Pleural Infiltration in the Blast Crisis Phase of Chronic Myeloid Leukemia: An Unusual Extramedullary Involvement.
V L; Jayaraman M; Kannan K; Priya L
Cureus; 2024 May; 16(5):e60121. PubMed ID: 38864064
[TBL] [Abstract][Full Text] [Related]
40. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
